Transcriptional profiles in melanocytes from clinically unaffected skin distinguish the neoplastic growth pattern in patients with melanoma

British Journal of Dermatology

Volumn 156, Issue 1, 2007, Pages 62-71

  Magnoni, C ^a   Tenedini, E ^a   Ferrari, F ^a   Benassi, L ^a   Bernardi, C ^a   Gualdi, G ^a   Bertazzoni, G ^a   Roncaglia, E ^a   Fantoni, L ^a   Manfredini, R ^a   Bicciato, S ^b   Ferrari, S ^a   Giannetti, A ^a   Tagliafico, E ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Gene expression profiling; Melanocytes; Melanoma; Microarrays; Transcriptome

Indexed keywords

TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SUSCEPTIBILITY; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOCYTE; MELANOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SUNLIGHT; ULTRAVIOLET B RADIATION;

ADULT; AGED; CASE-CONTROL STUDIES; CELL GROWTH PROCESSES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; SUNLIGHT; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; ULTRAVIOLET THERAPY;

EID: 33845515883     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07564.x     Document Type: Article

References (76)

1. Barnhill RL, Mihm MC Jr. The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol 1993; 10:47-75.
2. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003; 22:3099-112.
3. Lomuto M, Calabrese P, Giuliani A. Prognostic signs in melanoma: state of the art. J Eur Acad Dermatol Venereol 2004; 18:291-300.
4. Goldstein AM, Tucker MA. Genetic epidemiology of familial melanoma. Dermatol Clin 1995; 13:605-12.
5. Bataille V, Bishop JA, Sasieni P et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73:1605-11.
6. Chin L, Merlino G, DePinho RA. Malignant melanoma: modern black plague and genetic black box. Genes Dev 1998; 12:3467-81.
7. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42:705-22.
8. Sauter ER, Takemoto R, Litwin S et al. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther 2002; 9:807-12.
9. Sauter ER, Yeo UC, von Stemm A et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62:3200-6.
10. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003; 22:3053-62.
11. Talve L, Sauroja I, Collan Y et al. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74:255-9.
12. Kumar R, Sauroja I, Punnonen K et al. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 1998; 23:273-7.
13. Tsao H, Goel V, Wu H et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004; 122:337-41.
14. Poetsch M, Dittberner T, Woenckhaus C. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogenet 2001; 125:21-6.
15. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome. Oncogene 2003; 22:9217-24.
16. Reifenberger J, Knobbe CB, Sterzinger AA et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004; 109:377-84.
17. Kumar R, Angelini S, Czene K et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9:3362-8.
18. Omholt K, Platz A, Kanter L et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483-8.
19. Kraehn GM, Utikal J, Udart M et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 2001; 84:72-9.
20. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406:536-40.
21. Weeraratna AT, Jiang Y, Hostetter G et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1:279-88.
22. Clark EA, Golub TR, Lander ES et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406:532-5.
23. Garraway LA, Widlund HR, Rubin MA et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117-22.
24. Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581-6.
25. Ortonne JP. Photobiology and genetics of malignant melanoma. Br J Dermatol 2002; 146 (Suppl. 61):11-16.
26. Liu WM, Mei R, Di X et al. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 2002; 18:1593-9.
27. Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249-64.
28. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:5116-21.
29. Hosack DA, Dennis G Jr, Sherman BT et al. Identifying biological themes within lists of genes with EASE. Genome Biol 2003; 4:R70.
30. Burczynski ME, Twine NC, Dukart G et al. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 2005; 11:1181-9.
31. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast J 2003; 9:361-73.
32. Gombos Z, Xu X, Chu CS et al. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2005; 11:8364-71.
33. Soker S, Takashima S, Miao HQ et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92:735-45.
34. Takashima S, Kitakaze M, Asakura M et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA 2002; 99:3657-62.
35. Kunz M, Moeller S, Koczan D et al. Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 2003; 278:45651-60.
36. Grzeszkiewicz TM, Lindner V, Chen N et al. (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology 61 2002; 1441-50.
37. Mo FE, Muntean AG, Chen CC et al. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002; 22:8709-20.
38. Spencer JA, Hacker SL, Davis EC et al. Altered vascular remodeling in fibulin-5-deficient mice reveals a role of fibulin-5 in smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA 2005; 102:2946-51.
39. Ivkovic S, Yoon BS, Popoff SN et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003; 130:2779-91.
40. Kostourou V, Robinson SP, Cartwright JE et al. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 2002; 87:673-80.
41. Razzaq TM, Bass R, Vines DJ et al. Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4). J Biol Chem 2003; 278:42679-85.
42. Engelholm LH, List K, Netzel-Arnett S et al. uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol 2003; 160:1009-15.
43. van Leeuwen FN, Olivo C, Grivell S et al. Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J Biol Chem 2003; 278:400-6.
44. Weiner JA, Fukushima N, Contos JJ et al. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci 2001; 21:7069-78.
45. Schiemann WP, Blobe GC, Kalume DE et al. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem 2002; 277:27367-77.
46. Kwok WK, Ling MT, Lee TW et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65:5153-62.
47. Zagzag D, Shiff B, Jallo GI et al. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res 2002; 62:2660-8.
48. Spessotto P, Rossi FM, Degan M et al. Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. J Cell Biol 2002; 158:1133-44.
49. Podar K, Tai YT, Lin BK et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002; 277:7875-81.
50. Jawhari AU, Buda A, Jenkins M et al. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 2003; 162:69-80.
51. Martinez A, Vos M, Guedez L et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002; 94:1226-37.
52. Coll JL, Ben Ze'ev A, Ezzell RM et al. Targeted disruption of vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion, and locomotion. Proc Natl Acad Sci USA 1995; 92:9161-5.
53. Wenstrup RJ, Florer JB, Brunskill EW et al. Type V collagen controls the initiation of collagen fibril assembly. J Biol Chem 2004; 279:53331-7.
54. Faussillon M, Monnier L, Junien C et al. Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor. Cancer Lett 2005; 221:67-75.
55. Capobianco AJ, Zagouras P, Blaumueller CM et al. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol 1997; 17:6265-73.
56. Larsson C, Lardelli M, White I et al. The human NOTCH1, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p13.1 in regions of neoplasia-associated translocation. Genomics 1994; 24:253-8.
57. Hsieh JJ, Nofziger DE, Weinmaster G et al. Epstein-Barr virus immortalization: Notch2 interacts with CBF1 and blocks differentiation. J Virol 1997; 71:1938-45.
58. Jundt F, Probsting KS, Anagnostopoulos I et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103:3511-5.
59. Touab M, Villena J, Barranco C et al. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002; 160:549-57.
60. Zhan X, Bates B, Hu XG et al. The human FGF-5 oncogene encodes a novel protein related to fibroblast growth factors. Mol Cell Biol 1988; 8:3487-95.
61. Tien ES, Davis JW, Vanden Heuvel JP. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator. J Biol Chem 2004; 279:24053-63.
62. Khoo C, Blanchard RK, Sullivan VK et al. Human cysteine-rich intestinal protein: cDNA cloning and expression of recombinant protein and identification in human peripheral blood mononuclear cells. Protein Expr Purif 1997; 9:379-87.
63. Giampuzzi M, Botti G, Cilli M et al. Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 2001; 276:29226-32.
64. ten Berge D, Brouwer A, Korving J et al. Prx1 and Prx2 are upstream regulators of sonic hedgehog and control cell proliferation during mandibular arch morphogenesis. Development 2001; 128:2929-38.
65. Jones FS, Meech R, Edelman DB et al. Prx1 controls vascular smooth muscle cell proliferation and tenascin-C expression and is upregulated with Prx2 in pulmonary vascular disease. Circ Res 2001; 89:131-8.
66. Yang Y, Topol L, Lee H et al. Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development 2003; 130:1003-15.
67. Jonsson M, Andersson T. Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J Cell Sci 2001; 114:2043-53.
68. 2+ pathways. Oncogene 1999; 18:7860-72.
69. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006; 21:3-9.
70. Vecchione A, Ishii H, Baldassarre G et al. FEZ1/LZTS1 is downregulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. Am J Pathol 2002; 160:1345-52.
71. Gilbertson DG, Duff ME, West JW et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 2001; 276:27406-14.
72. Lazar-Molnar E, Hegyesi H, Toth S et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12:547-54.
73. Halaban R, Cheng E, Smicun Y et al. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000; 191:1005-16.
74. Hoek K, Rimm DL, Williams KR et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004; 64:5270-82.
75. Elwood JM. Melanoma and sun exposure. Semin Oncol 1996; 23:650-66.
76. Whiteman DC, Watt P, Purdie DM et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806-12.